Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0257

ORIGINAL RESEARCH

Discovering novel genes and druggable mutations in gastric cancer by applying Next-Generation Sequencing.

Prof. Theodore Liakakos, MD, PhD

Affiliation: Theodore Liakakos, MD, Professor of Surgery, Head of 1st Department of Surgery, National Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

E-mail: theodlia@otenet.gr

Abstract
Background: Slow progress in understanding molecular mechanisms of tumorigenesis, metastasis and therapeutic resistance are reflected by substantially cancer-related death-rates in stages II, III and IV.
Methods: Rapid progress and validity of Next-Generation Sequencing (NGS) to identify genetic heterogeneity has led us to perform whole exome sequencing (WES) normal cancer tissue paired in gastric cancer patients. Aim of this study was to identify novel cancer driver genes and mutations with clinical revelation.
Results:
Several new gastric cancer driver genes and mutations have been highlighted by our statistical analysis. Two of these genes might have clinical implications as biomarkers and/or druggable mutations.
Conclusion: Large patient centric WES trials are required for valid identification of novel oncotarget based drug development and new predictive biomarkers. This strategy could improve personalized treatment of gastric cancer.

(Citation: Gastric & Breast Cancer 2017; 12(1): 20-30)

Back
You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 25 February 2017